Clin. lab. Haemat. 1985, **7**, 393–396

Author index to Volume 7

AKINYANJO O.O. In-vivo neutrophil migration and nitroblue tetrazolium reduction in sickle cell disease 133
AL SHARANI S., *see* LAWSON A.T. & AL SHAHRANI S.
ANDERSON L.M., *see* HINCHCLIFFE R.F. *et al.*
ANDREWS C., CROCKARD A.D., SAN MIGUEL J.F. & CATOVSKY D. Dipeptidylamino-peptidase IV(DAP IV) in B- and T-cell leukaemias 359

BALL S., *see* HEGDE U.M. *et al.*
BECKFORD M., *see* MAUDE G.H. *et al.*
BELLINGHAM A.J., *see* CHU P. *et al.*
BENTLEY D.P., *see* LITTLEWOOD T.J. *et al.*
BHARUCHA C. & MAGENNIS H. Fresh frozen plasma in the treatment of autoimmune thrombocytopenic purpura in adults: evidence for the potentiating effect of vincristine 119
BLACKMORE J.A., *see* PARRY T.E. *et al.*
BLECHER T.E., *see* GOZZARD D.I. *et al.*
BOTTOMLEY J., *see* KELSEY P.R. *et al.*
BRIEN W.F., MANT M.J. & ETCHES W.S. Variant congenital dyserythropoietic anaemia with ringed sideroblasts 231
BROZOVIC B., *see* ROBBINS G. *et al.*

CADLEY M., *see* CHU P. *et al.*
CATOVSKY D., *see* ANDREWS C. *et al.*
CATOVSKY D., *see* KEIDAN A.J. *et al.*
CATOVSKY D., *see* PEREIRA A.M. *et al.*
CATOVSKY D., *see* MEHTA A.B. *et al.*
CHANTARANGKUL V., *see* CUGNO M.M. *et al.*
CHU P., CADLEY M. & BELLINGHAM A.J. Red cell metabolism in renal failure—the effect of dialysis 1
CLARK S.J., *see* HINCHCLIFFE R.F. *et al.*
CLARKE P.T., HENTHORN J.S. & ENGLAND J.M. Differential white cell counting on the Coulter Counter Model S Plus (three population) and the Technicon H6000: a comparison by simple and multiple regression 335
COCKRAN K.M., *see* SHEEHAN T. *et al.*
CONTRERAS M., *see* DE SILVA M. & CONTRERAS M.
CROCKARD A.D., *see* ANDREWS C. *et al.*
CUGNO M.M., CHANTARANGKUL V., TRIPODI A. & MANNUCCI R.M. Assessment of a new instrument (Coag-A-Mate X2) for performing global clotting tests and specific factor assays 75

DALY H.M., MORSE C. & SCOTT G.L. Case report: Diagnosis of *Salmonella* osteomyelitis in a neutropenic patient using ^{111}Indium-labelled donor leucocytes 177
DAVEY F.R., KUREC A.S. & OATES R.P. Cell volumes of lymphoblasts in patients with acute lymphocytic leukaemia 17
DAVIS H.P., TREACY M., PARKER D. & DUGGAN G. Case report: Uncomplicated administration of blood products warmed to 37°C in a patient with T activation of the red cell membrane 173
DE BRUYERE M.J.G., *see* LEYSEEN M.H.J. *et al.*
DE SILVA M. & CONTRERAS M. Polled cells versus individual screening cells in pre-transfusion testing 369
DOUAY L., *see* LOPEZ M. *et al.*
DUGGAN G., *see* DAVIS H.P. *et al.*
DU PUY-MONTBRUN M.-C., *see* LOPEZ M. *et al.*

EMERSON P.M., *see* MONTCRIEFF M.W. *et al.*
ENGLAND J.M., *see* CLARKE P. *et al.*
ETCHES W.S., *see* BRIEN W.F. *et al.*

FINNEY R.D., *see* WILLIAMS M.D. *et al.*
FRENCH E.A., *see* GOZZARD D.I. *et al.*
FUCHAROEN S., *see* WICKRAMASINGHE S.N. *et al.*

GHOSH S. & PATTON L. Complications of therapeutic plasma exchange 219

GILL D.S. & WICKRAMASINGHE S.N. *et al.* Changes in the uptake of ^{57}Co-cyanocobalamin during dimethylsulphoxide-induced differentiation of HL60 cells to neutrophils 143
GLASS U.H., *see* KESTEVEN P.J.L. *et al.*
GORIN N.C., *see* LOPEZ M. *et al.*
GOZZARD D.I., FRENCH A.E., BLECHER T.E. & POWELL R.J. C-reactive protein levels in neutropenic patients with pyrexia 307
GRANDISON Y., *see* MAUDE G.H. *et al.*
GRAUER F., *see* HERSHKO C. *et al.*
GROTTE G.J., *see* KELSEY P.R. *et al.*

HEGDE U.M., ZUIABLE A., BALL S. & ROTER B.L.T. The relative incidence of idiopathic and secondary autoimmune and thrombocytopenia: a clinical and serological evaluation in 508 patients 7
HUGHES M., *see* WICKRAMASINGHE S.N. *et al.*
HENTHORN J.S., *see* CLARK P.J. *et al.*
HERSHKO C., KONIJN A.M., LINK G., MOREB J., GRAUER F. & WEISSENBERG E. Combined use of zinc protophorin (ZPP), mean corpuscular volume and haemaglobin measurement for classifying microcytic RBC disorders in children and young adults 259
HEWITT J. & REARDON D.M. Neutrophil mean peroxidase: a biologically interesting parameter with a potential for WBC differential quality control 33
HIGGS D.R., *see* MAUDE G.H. *et al.*
HINCHCLIFFE R.F., LAYCOCK B.J., CLARKE S.J., MORTON J., ANDERSON L.M. & LILLEYMAN J.S. An evaluation of the Sequoia-Turner cell Dyn 900 157
HUEHNS E.R., *see* MARCUS R.E. & HUEHNS E.R.
HUTCHINSON D., *see* REARDON D.M. *et al.*

INTERNATIONAL COMMITTEE FOR STANDARDIZATION IN HAEMATOLOGY Recommended methods for cytological procedures in haematology 55

JONES L. & NEWLAND A.C. Case report: C1 esterase inihibitor as a possible tumour marker in malignant lymphoma 279

KEARNEY L., *see* MEHTA A.B. *et al.*
KEIDAN A.J., CATOVSKY D., TAVARES DE CASTRO J. & SPRY C.J.F. Case report: Hypereosinophilic syndrome preceding T cell lymphoblastic lymphoma 83
KELSEY P.R., BOTTOMLEY J., GROTTE G.J. & MACIVER J.E. Case report: Congenital factor XII deficiency: successful open heart surgery and anticoagulation 377
KESTEVEN P.J.L., PULLAN J.M., GLASS U.H. & WETHERLEY-MEIN G. Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders 297
KOEPKE J.A., *see* WILEY J.F. & KOEPKE J.A.
KONIJN A.M., *see* HERSHKO C. *et al.*
KUREC A. S., *see* DAVEY F.R. *et al.*

LAPORTE J.-P., *see* LOPEZ M. *et al.*
LAURENCE A.S., *see* PARRY T.E. *et al.*
LAWSON A.T. & AL SHARANI S. Technical note: A rapid technique for the estimation of fibrinogen 167
LAYCOCK B.J., *see* HINCHCLIFFE R.F. *et al.*
LEWIS S.M., *see* WARDLE J. *et al.*
LEYSSEN M.H.J., DE BRUYERE M.J.G., VAN DUPPEN V.J.M. & VERWILGHEN R.L. Problems related to CPD preserved blood used for NEQAS trials in haematology 239
LILLEYMAN J.S., *see* HINCHCLIFFE R.F. *et al.*
LINK G., *see* HERSHKO C. *et al.*
LITTLEWOOD T.J., SPRAGG B.P. & BENTLEY D.P. When is autologous bone marrow transplantation safe after high dose treatment with etoposide? 213
LOPEZ M., DU PUY-MONTBRUN M.-C., DOUAY L., LAPORTE J.-P. & GORIN N.C. Standardization and characterization of the procedure for *in vivo* treatment of human bone marrow with cyclophosphamide derivatives 327

MACIVER J.E., *see* KELSEY P.R. *et al.*
MACKIE M.J., *see* STRANGE C.A. *et al.*
MAGENNIS H., *see* BHARUCHA C. & MAGENNIS H.
MAJUMDAR G. & PAYNE R.W. Quality control of oral anticoagulant therapy 125
MANNUCCI P.M., *see* CUGNO M.M. *et al.*
MANT M.J., *see* BRIEN W.F. *et al.*
MARCUS R.E. & HUEHNS E.R. Review: Transfusional iron overload 195
MARNELL J.H., *see* STRANGE C.A. *et al.*
MASON K., *see* MAUDE G.H. *et al.*
MAUDE G.H., HIGGS D.R., BECKFORD M., GRANDISON Y., MASON K., TAYLOR B.,

SERJEANT B.E. & SERJEANT G.R. Alpha thalassaemia and the haematology of normal Jamaican children 289
MCEVOY P., *see* STRANGE C.A. *et al.*
MEHTA A.B., TAVARES DE CASTRO J., SAN MIGUEL J.F., YIN J.A.L., O'BRIEN M., KEARNEY L. & CATOVSKY D. Osteolytic lesion as the presenting feature of chronic granulocytic leukaemia 105
MELVILLE D., *see* PAUL F. *et al.*
MONCRIEFF M.W., EMERSON P.M., WINDEBANK K.P. & SHEPARD L.E. Case report: Acute lymphoblastic leukaemia presenting with hypercalcaemia 271
MOREB J., *see* HERSHKO C. *et al.*
MORSE C., *see* DALY H.M. *et al.*
MORTON J., *see* HINCHCLIFFE R.F. *et al.*

OATES R.P., *see* DAVEY F.R. *et al.*
O'BRIEN M., *see* MEHTA A.B. *et al.*
O'DONNELL J.R., *see* SHEEHAN T. *et al.*

PARKER D., *see* DAVIS H.P. *et al.*
PARRY T.E., LAURENCE A.S., BLACKMORE J.A. & ROBERTS B. Serum valine, methionine and isoleucine in patients anaesthetized with and without nitrous oxide 317
PATON L., *see* GHOSH S. & PATON L.
PAUL F., MELVILLE D. & ROATH S. The morphology and viability of blood components processed by high gradient magnetic separation 43
PAYNE R.W., *see* MAJUMDAR G. & PAYNE R.W.
PEREIRA A.M., TAVARES DE CASTRO J., SANTOS E.G., PERLOIRO M.C. & CATOVSKY D. Case report: T lymphoblastic transformation of refractory anaemia with excess of blasts 89
PERLOIRO M.C., *see* PEREIRA A.M. *et al.*
PETERSON C.V., *see* ROBBINS G. *et al.*
POWELL R.J., *see* GOZZARD D.I. *et al.*
PRESTON F.E., *see* REARDON D.M. *et al.*
PULLAN J.M., *see* KESTEVEN P.J.L. *et al.*

REARDON D.M., HUTCHINSON D., PRESTON F.E. & TROWBRIDGE E.A. The routine measurement of platelet volume: a comparison of aperture-impedance and flow cytometric systems 251
REARDON D.M., *see* HEWITT J. & REARDON D.M.
ROATH S., *see* MELVILLE D. *et al.*
ROBERTS B., *see* PARRY T.E. *et al.*
ROBBINS G., PETERSON C.V. & BROZOVIC B. Lymphocytopenia in donors undergoing regular platelet apheresis with cell separators 225
ROTER B.L.T., *see* HEGDE U.M. *et al.*

SAN MIGUEL J.F., *see* ANDREWS C. *et al.*
SAN MIGUEL J.F., *see* MEHTA A.B. *et al.*
SANTOS E.G., *see* PEREIRA A.M. *et al.*
SCOTT G.L., *see* DALY H.M. *et al.*
SERJEANT B.E., *see* MAUDE G.H. *et al.*
SERJEANT G.R., *see* MAUDE G.H. *et al.*
SHEEHAN T., SINCLAIR D., TANSEY P. & O'DONNELL J.R. Case report: The potential value of immuno-isoelectric focusing in the management and diagnosis of solitary plasmacytoma 374
SHEEHAN T., TANSEY P., COCHRAN K.M. & O'DONNELL J.R. Case report: Inflammatory bowel disease, anaemia and sulphasazine 275
SHEPERD L.E., *see* MONCRIEFF M.W. *et al.*
SHINTON N.K., *see* WILLIAMS M.D. *et al.*
SINCLAIR D., *see* SHEEHAN T. *et al.*
SPRAGG B.P., *see* LITTLEWOOD T.J. *et al.*
SPRY C.J.F., *see* KEIDAN A.J. *et al.*
STRANGE C.A., MACKIE M.J., MARNELL J.H. & MCEVOY P. An assessment of the Ortho ELT-800 WBC and three part WBC screen 151

TANSEY P., *see* SHEEHAN T. *et al.*
TANSEY P., *see* SHEEHAN T. *et al.*
TAVARES DE CASTRO J., *see* PEREIRA A.M. *et al.*
TAVARES DE CASTRO J., *see* KEIDAN A.J. *et al.*
TAVARES DE CASTRO J., *see* MEHTA A.B. *et al.*
TAYLOR B., *see* MAUDE G.H. *et al.*
TREACY M., *see* DAVIS H.P. *et al.*
TRIPODI A., *see* CUGNO M.M. *et al.*
TROWBRIDGE E.A., *see* REARDON D.M. *et al.*

VAN DUPPEN V.J.M., *see* LEYSSEN M.H.J. *et al.*
VERWILGHEN R.L., *see* LEYSSEN M.H.J. *et al.*

WARD P.G., *see* WARDLE J. *et al.*
WARDLE J., WARD P.G. & LEWIS S.M. Response of various blood counting systems to CPD-A1 preserved whole blood 245
WASI P., *see* WICKRAMASINGHE S.N. *et al.*
WEISSENBERG E., *see* HERSHKO C. *et al.*

WETHERLEY-MEIN G., *see* KESTEVEN P.J.L. *et al.*

WICKRAMASINGHE S.N., HUGHES M., FUCHAROEN S. & WASI P. The morphology of redox-dye treated HbH-containing red cells: differences between cells treated with brilliant cresyl blue, methylene blue and new methylene blue 353

WICHRAMASINGHE S.N., *see* GILL D.S. & WICKRAMASINGHE S.N.

WILEY J.F. & KOEPKE J.A. Changes in serum potassium in premature infants receiving packed red blood cells 27

WILLIAMS M.D., SHINTON N.K. & FINNEY R.D. Primary acquired sideroblastic anaemia and myeloproliferative disease: a report of three cases 113

WINDEBANK K.P., *see* MONTCRIEFF M.W. *et al.*

YIN J.A.L., *see* MEHTA A.B. *et al.*

ZUIABLE A., *see* HEGDE U.M. *et al.*

Clin. lab. Haemat. 1985, **7**, 397–398

Subject index to Volume 7

Alpha thalassaemia, haematology of Jamaican children 289
Anaemia
  inflammatory bowel disease and sulphasalazine 275
  primary sideroblastic 113
  refractory with excess blasts 89
  variant congenital dyserythropoietic with ringed sideroblasts 231
Anticoagulant therapy, quality of oral 125

Bone marrow
  treatment with cyclophosphamide derivatives 327
  transplantation, after high dose treatment with etoposide 213
Bowel disease, anaemia and sulphasalazine 275

C1 esterase inhibitor, as marker 279
^{57}Co-cyanocobalamin, uptake during differentiation of HL60 cells to neutrophils
Coag-A-Mate X2, assessment 75
CPD preserved blood in NEQAS trials 239
CPD-Al preserved blood, response of counting systems 245
Cyclophosphamide derivatives, bone marrow treatments 327
Cytological procedures in haematology 55

Dialysis, effect on cell metabolism in renal failure 1
Dimethylsulphoxide, differentiation of HL60 cells to neutrophils 143
Dipeptidylaminopeptidase IV, and leukaemia 359

Etoposide, marrow transplant after high dose treatment 213

Factor XII deficiency 377
Fibrinogen, rapid estimation 167

Global clotting, Coag-A-Mate X2 75

HbH-containing red cells 353
Heart surgery, factor XII deficiency 377
Hypereosinophilic syndrome, preceding T cell lymphoblastic lymphoma 83
Hypersplenism, in myeloproliferative and lymphoproliferative disorders 297

Immuno-isoelectric focusing 374
^{111}Indium, labelled donor cells—diagnosis for *Salmonella* 177
Iron overload, in transfusion 195

Jamaican children, haematology 289

Leukaemia
  acute lymphoblastic presenting with hypercalcaemia 271
  chronic granulocytic with osteolytic lesion 105
  lymphocytic, cell volume of lymphoblasts 17
Lymphocytopenia in donors undergoing platelet apheresis 225
Lymphoma, C1 esterase inhibitor as possible tumour marker 279

Magnetic separation, morphology and viability of blood components 43
Marker, C1 esterase for tumours 279
Myeloproliferative disease 113

NEQAS trials, CPD preserved blood 239
Neutropenia
  C-reactive protein levels in patients with pyrexia 407
  diagnosis of *Salmonella* osteomyelitis 177
Neutrophil
  mean peroxidase 33
  migration in sickle cell disease 133
Nitrous oxide anaesthetic, serum valine, methionine and isoleucine 317

Ortho ELT-800, three part WBC assessment 151

Osteolytic lesion, presenting in leukaemia 105

Plasma exchange, complications of therapeutic 219
Plasma, fresh frozen in treatment of thrombocytopenic purpura 119
Platelet apherisis, lymphocytopenia in donors 225
Platelet volume, aperture-impedance and flow cytometric systems 251
Potassium, serum changes in infants receiving packed RBC 27
Premature infants, serum potassium changes 27
Procedures in haematology, recommended cytological 55

Red blood cells
containing HbH 353
membrane, T-activation—uncomplicated administration of blood products at 37°C 173
metabolism in renal failure, effect of dialysis 1
microcytic disorders, classification by ZZP, MCV and haemaglobin 259
Renal failure, dialysis and red cell metabolism 1

Salmonella osteomyelitis in neutropenic patient 177
Sequoia-Turner Cell Dyn 900, evaluation 157
Sickle cell disease, neutrophil migration and nitroblue tetrazolium 133
Splenectomy, in lymphoproliferative and myeloproliferative disorders 397
Sulphasalazine, bowel disease and anaemia 275

T cell lymphoblastic lymphoma 83
Tetrazolium, in sickle cell disease 133
Thrombocytopenia, secondary autoimmune and idiopathic 7
Thrombocytopenic purpura, treatment with plasma 119
T lymphoblastic, transformation of anaemia with excess blasts 89
Transfusion, iron overload 195
Transfusion, pre-transfusion testing 469
Tumour, C1 esterase inhibitor as marker 279

White blood cell
screen, three part assessment 151
counting, Coulter Counter S Plus IV and Technicon H6000 435
differential quality control, neutrophil mean peroxidase 33

Zinc protophorin, MCV and haemaglobin, classification of microcytic RBC disorders 259